Tesamorelin

£50.00

Third-party tested

1–2 day tracked dispatch

Discreet packaging

99%+ purity guaranteed

For Research Use OnlyThis compound is strictly for laboratory and in-vitro research. Not for human consumption or medical use.

Reconstitution

Pen format? Pens are supplied pre-mixed and ready for research use — no reconstitution required. The steps below apply to lyophilized vials only.

Swab both vial stoppers with alcohol and allow to dry.
Draw the required volume of bacteriostatic water with a sterile syringe.
Add the water slowly down the inside wall of the vial — never directly onto the powder.
Swirl gently until fully dissolved. Never shake.
Confirm the solution is clear and particle-free.
Label with date and concentration, then refrigerate at 2–8 °C.

Full guide & dose calculator

Storage & Handling

Lyophilized vials: refrigerate sealed at 2–8 °C away from light; freeze at −20 °C for storage beyond 6 months.
After reconstitution: refrigerate at 2–8 °C; typically stable 4–8 weeks with bacteriostatic water. Do not freeze once mixed.
Pre-mixed pens: arrive ready to use — refrigerate at 2–8 °C with the cap on and never freeze.
General: avoid direct sunlight, heat and repeated temperature swings; minimise agitation.

Quality & Shipping FAQ

Is this compound tested? Yes — every batch is third-party tested by accredited labs (HPLC & mass spectrometry) at 99%+ verified purity.
How is it supplied? As lyophilized powder in a sealed sterile vial (or pre-mixed pen where offered), with research-use labelling.
How fast is dispatch? 1–2 working day dispatch, 2–3 days UK delivery, in plain discreet packaging.
What is it for? Strictly laboratory and in-vitro research — not for human or veterinary consumption, medical use or self-administration.

View the peer-reviewed research

Packaging update Our branded boxes are temporarily out of stock. Until new stock lands, orders ship in plain, discreet packaging — the same product inside, sealed and dispatched with the same care. Thank you for your patience.

Tesamorelin

Tesamorelin is a synthetic, stabilised analogue of growth-hormone-releasing hormone (GHRH). It is used as a reference compound in endocrinology research examining the GHRH receptor and the growth-hormone axis.

About the compound

Tesamorelin has been the subject of published clinical and preclinical research investigating GHRH-receptor signalling and pulsatile growth-hormone regulation in laboratory and trial settings. It remains a widely referenced compound in metabolic and endocrine research.

Specifications

Purity: 99%+ (third-party verified)
Independently tested before dispatch
Presented as lyophilised (freeze-dried) powder
Supplied for in-vitro laboratory research only

FAQ

Is it tested? Yes — every batch is independently tested to 99%+ purity before dispatch.
What form does it arrive in? Lyophilised powder.
What is this sold for? Laboratory and research use only. Not for human or animal consumption.

⚖ For Laboratory Research Use Only — Not for Human Consumption.

Tesamorelin Growth Peptides Human RCT

Tesamorelin: Significant Visceral Fat Reduction in Randomised Human Clinical Trial

New England Journal of Medicine · Falutz et al., 2007

A randomised, double-blind, placebo-controlled trial in 412 adults demonstrated tesamorelin produced a 15.2% reduction in visceral adipose tissue vs 5.1% for placebo over 26 weeks. Participants also showed significant improvements in triglyceride levels, waist circumference, and quality-of-life scores. This robust human evidence supported FDA approval of tesamorelin (Egrifta) for excess abdominal fat in HIV-infected adults.

Human RCT Visceral Fat FDA Approved

Tesamorelin Growth Peptides Human RCT

Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV

New England Journal of Medicine · Falutz et al., 2007

A phase 3 randomised placebo-controlled trial of tesamorelin, a GHRH analogue, in patients with HIV-associated abdominal fat accumulation. Daily subcutaneous tesamorelin significantly reduced visceral adipose tissue relative to placebo while largely sparing subcutaneous fat, with favourable effects on triglycerides. Discontinuation led to re-accumulation, indicating the effect is treatment-dependent.

GHRH Analogue Visceral Fat Human RCT

View the full research library →